KR930702306A - 소염제/알레르기 치료제로서의 나프탈렌프로피온산 유도체 - Google Patents

소염제/알레르기 치료제로서의 나프탈렌프로피온산 유도체

Info

Publication number
KR930702306A
KR930702306A KR1019930700676A KR930700676A KR930702306A KR 930702306 A KR930702306 A KR 930702306A KR 1019930700676 A KR1019930700676 A KR 1019930700676A KR 930700676 A KR930700676 A KR 930700676A KR 930702306 A KR930702306 A KR 930702306A
Authority
KR
South Korea
Prior art keywords
formula
lower alkyl
compound
hydrogen
quinolinylmethoxy
Prior art date
Application number
KR1019930700676A
Other languages
English (en)
Inventor
프랑크 크레프트 3세 안토니
헨리 머서 존
자콥 빅슬러 제임스
윌리암 기버슨 존
마틴 쿠브락 데니스
리 반커 안네트
Original Assignee
에곤 이.버그.
아메리칸 홈 프로덕츠 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에곤 이.버그., 아메리칸 홈 프로덕츠 코포레이션 filed Critical 에곤 이.버그.
Publication of KR930702306A publication Critical patent/KR930702306A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

본 발명에는 일반식(I)의 화합물, 약제학적으로 허용되는 이의 염, 및 류코트리엔-매개된 비기관지의 폐색성 기도 질환(예:알레르기성 비염, 알레르기성 천식 등), 건선, 궤양성 대장염, 류마티스성 관절염 및 기타 직접적인 과감작 반응을 치료하는데 있어서의 이의 용도가 기술되어 있다.
상기식에서, A는 탄소수 3 내지 19의 알킬, 디저급알킬 비닐, 디할로비닐, 저급 알키닐,이고, W는 -CR2O-, -CH=CH- 또는 -CH=CHCH2O-이며, X는 N 또는 CR이고, Z는-S- 또는 -O-이며, R은 수소 또는 저급 알킬이고, Y는NROH이며, 단, W가 CH2O이면,(여기서, R3은 OR이 아니다)이고, R1은 수소, 저급 알킬 또는 페닐이며, R2는 수소 또는 저급 알킬이거나, R1및 R2가 함께 할로에 의해 임의로 치환된 벤젠 환을 형성하고, R3은 -OR,또는 -NHSO2R4이며, R4는 페닐 또는 저급 알킬 치환된 페닐이고, R5는 수소 또는 할로이다.

Description

소염제/알레르기 치료제로서의 나프탈렌프로피온산 유도체
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (32)

  1. 하기 일반식(I)의 화합물 및 약제학적으로 허용되는 이의 염.
  3. 상기식에서, A는 탄소수 3 내지 19의 알킬, 디저급알킬 비닐, 디할로비닐, 디페닐비닐, 저급 알키닐,
  4. 이고, W는 -CR2O-, -CH=CH- 또는 CH=CHCH2O-이며, X는 N 또는 CR이고, Z는또는 -O- 이며, R은 수소 또는 저급 알킬이고, Y는NROH이며, 단, W가 CH2O이면,(여기서 R3은 OR이 아니다)이고, R1은 수소, 저급 알킬 또는 페닐이며, R2는 수소 또는 저급 알킬이거나, R1및 R2가 함께 할로에 의해 임의로 치환된 벤젠 환을 형성하고, R3은 -OR,또는 -NHSO2R4이며, R4는 페닐 또는 저급 알킬 치환된 페닐이고, R5는 수소 또는 할로이다.
  5. 제1항에 있어서, α-메틸-6-[(7-클로로-2-퀴놀리닐)메톡시]-2-나프탈렌아세트산, α-메틸-5-브로모-6-(2-퀴놀리닐메톡시)-2-나프탈렌아세트산, α-메틸-6-[(3-페닐-2-프로페닐)옥시]-2-나프탈렌아세트산, 6-(2-퀴놀리닐메톡시)-2-나프탈렌아세트산, α,α-디메틸-6-(2-퀴놀리닐메톡시)-2-나프탈렌아세트산, N-하이드록시-α-N-디메틸-6-(2-퀴놀리닐메톡시)-2-나프탈렌아세트아미드, (S)-N-하이드록시-α-N-디메틸-6-(2-퀴놀리닐메톡시)-2-나프탈렌아세트아미드,α-메틸-N-[(4-메틸페닐)설포닐]-6-(2-퀴놀리닐메톡시)-2-나프탈렌아세트아미드, (S)-β-메틸-6-(2-퀴놀리닐메톡시)-2-나프탈렌에탄올, (S)-α-메틸-6-(2-퀴놀리닐메톡시)-2-나프탈렌아세트알데히드, N-메톡시-α-메틸-6-(2-퀴놀리닐메톡시)-2-나프탈렌아세트아미드, (-)-N-[1-[6-(2-퀴놀리닐메톡시)-2-나프탈레닐]에틸]-N-하이드록시 우레아 또는 약제학적으로 허용되는 이들의 염인 일반식(I)의 화합물.
  6. 제1항에 있어서, 약제로서 사용하기 위한, Y가(여기서, R은 저급 알킬이다)이고, A, W, Z, R, R1및 R2가 제1항에서 정의한 바와 같은 일반식(I)의 화합물.
  7. 제1항에 있어서, 약제로서 사용하기 위한, α-메틸-6-(2-퀴놀리닐메톡시)-2-나프탈렌아세트산 메틸에스테르 또는 약제학적으로 허용되는 이의 염인 일반식(I)의 화합물.
  8. 제1항에 있어서, 약제로서 사용하기 위한, (S)-α-메틸-6-(2-퀴놀리닐메톡시)-2-나프탈렌아세트산메틸 에스테르 또는 약제학적으로 허용되는 이의 염인 일반식(I)의 화합물.
  9. 제1항에 있어서, N-하이드록시-N′-[1-메틸-1-[6-(2-퀴놀리닐메톡시)-2-나프탈레닌]에틸]우레아, α,α-디메틸-6-(2-벤조티아졸릴메톡시)-2-나프탈렌아세트산, (-)-N-하이드록시-N′-[1-[6-(2-페닐-4-티아졸릴)메톡시-2-나프탈레닐]에틸]우레아, N-[1-[6-(2-벤조티아졸릴메톡시)-2-나프탈레닐]-1-메틸에틸]-N′-하이드록시우레아, S-(-)-N-[1-[6-(2-벤조티아졸릴메톡시)-2-나프탈레닐]에틸]-N′-하이드록시우레아, S-(+)-N-하이드록시-α,N-디메틸-[6-(2-페닐-4-티아졸릴)메톡시-2-나프탈렌아세트아미드, N-하이드록시-α,α,N-트리메틸-6-(2-벤조티아졸릴메톡시)-2-나프탈렌아세트아미드, S-(-)-N-하이드록시-α-메틸-N-(1-메틸에틸)-6-(2-퀴놀리닐메톡시)-2-나프탈렌아세트아미드, N-하이드록시-N-메틸-N′-[1-[(S)-6-(2-퀴놀리닐메톡시)-2-나프탈레닐]에틸]우레아, S-(+)-N-하이드록시-α,N-디메틸-6-(2-벤조티아졸릴메톡시)-2-나프탈렌아세트아미드, N-하이드록시-α,α-N-트리메틸-6-(2-퀴놀리닐메톡시)-2-나프탈렌아세트아미드, S-(+)-N-하이드록시-α,N-디메틸-6-(2-피리디닐메톡시)-2-나프탈렌아세트아미드, S-(+)-N-하이드록시-α,N-디메틸-6-[(1-메틸-1H-벤즈이미다졸-2-일)메톡시]-2-나프탈렌아세트아미드, S-N-하이드록시-α,N-디메틸-6-(2-벤조옥사졸릴메톡시)-2-나프탈렌아세트아미드, N-하이드록시-N-메틸-6-(2-퀴놀리닐메톡시)-2-나프탈렌아세트아미드 또는 약제학적으로 허용되는 이들의 염인 일반식(I)의 화합물.
  10. (S)-(+)-N-하이드록시-α,N-디메틸-6-(2-벤조티아졸릴메톡시)-2-나프탈렌아세트아미드 나트륨염.
  11. 일반식(Ⅱ)의 화합물을 일반식(Ⅲ)의 화합물의 금속 유도체 1당량과 반응시킴을 특징으로 하여, 일반식(I)의 화합물을 제조하는 방법.
  13. 상기식에서, P는 CR2또는 CH=CHCH2-이고, Hal은 염소, 브롬 또는 요오드이며, A, Y 및 R5는 제1항에서 정의한 바와 같다.
  14. 일반식(Ⅱ)의 화합물을 일반식(Ⅲa)의 화합물의 금속유도체 2당량과 반응시켜 일반식(Ⅳ)의 에테르 에스테르를 수득한 다음, 당해 에테르 에스테르를 가수분해시켜 일반식(Ⅰ)의 화합물을 수득하고, 필요에 따라, 당해 생성물을 약제학적으로 허용되는 이의 염으로 분리시킴을 특징으로 하여,(여기서, R은 수소 또는 저급 알킬이다)이고, 단 Y가인 경우 W는 CH2O가 아닌 제1항에 따른 일반식(I)의 화합물을 제조하는 방법.
  16. 상기식에서, A, W 및 R5는 제1항에서 정의한 바와 같고, P는 제8항에서 정의한 바와 같으며, Y는 위에서 정의한 바와 같다.
  17. 일반식(Ⅳa)의 화합물을 가수분해시킨 다음, 필요에 따라, 당해 생성물을 약제학적으로 허용되는 염으로 분리시킴을 특징으로 하여, Y가(여기서, R은 수소 또는 저급 알킬이다)이고, 단 Y가인 경우 W는 CH2O가 아닌 제1항에 따른 일반식(I)의 화합물을 제조하는 방법.
  19. 상기식에서, A, R5및 W는 제1항에서 정의한 바와 같되, 상기 단서 조항이 적용된다.
  20. 일반식(I)의 산의 상응하는 저급 알킬 에스테르를 가수분해시킨 다음, 필요에 따라, 당해 생성물을 약제학적으로 허용되는 염으로 분리시킴을 특징으로 하여, Y가이고, 단 Y가인 경우 W는 CH2O가 아닌 일반식(I)의 화합물 또는 약제학적으로 허용되는 이의 염을 제조하는 방법.
  21. Y가인 일반식(I)의 상응하는 화합물을 환원시킴을 특징으로 하여, Y가(여기서, R은 수소 또는 저급 알킬이다)인 제1항에 다른 일반식(I)의 화합물을 제조하는 방법.
  22. Y가인 일반식(I)의 상응하는 산 클로리아드를 저급 알킬 하이드록실아민으로 처리함을 특징으로 하여, Y가(여기서, R은 수소 또는 저급 알킬이고, R6은 저급 알킬이다)인 제1항에 따른 일반식(I)의 화합물을 제조하는 방법.
  23. Y가인 일반식(I)의 상응하는 산을 카보디이미드의 존재하에 O-알킬 하이드록실아민으로 처리함을 특징으로 하여, Y가(여기서, R은 수소 또는 저급 알킬이고, R6은 저급 알킬이다)인 제1항에 따른 일반식(I)의 화합물을 제조하는 방법.
  24. Y가(여기서, R은 수소 또는 저급 알킬이다)인 일반식(I)의 산 아지드를 하이드록실아민 또는 N-저급 알킬 하이드록실아민으로 처리함을 특징으로 하여, Y가(여기서, R은 수소 또는 저급 알킬이다)인 제1항에 따른 일반식(I)의 화합물을 제조하는 방법.
  25. Y가인 일반식(I)의 상응하는 산을 축합제의 존재하에 일반식 R4SO2NH2(여기서, R4는 페닐 또는 저급 알킬 치환된 페닐이다)의 벤젠 설폰아미드로 처리함을 특징으로 하여, Y가[여기서, R3은 NHSO2R4(여기서, R4는 위에서 정의한 바와 같다)이고, R은 수소 또는 저급 알킬이다]인 제1항에 따른 일반식(I)의 화합물을 제조하는 방법.
  26. Y가인 일반식(I)의 상응하는 알콜을 산화시킴을 특징으로 하여, Y가(여기서, R은 수소 또는 저급 알킬이다)인 제1항에 따른 일반식(I)의 알데히드를 제조하는 방법.
  27. Y가인 일반식(I)의 상응하는 산을 에스테르화시킴을 특징으로 하여, Y가(여기서, R은 수소 또는 저급 알킬이고, R6은 저급 알킬이다)이고, 단 Y가(여기서, R5는 저급 알킬이다)인 경우 W는 CH2O가 아닌 제1항에 따른 일반식(I)의 에스테르를 제조하는 방법.
  28. 제8항 내지 제18항 중의 어느 한 항에 따른 방법에 의해 제조된 일반식(I)의 화합물.
  29. 제1항 내지 제7항 중의 어느 한 항에 따른 방법에 의해 제조된 일반식(I)의 화합물 및 약제학적으로 허용되는 담체를 포함하는 약제학적 조성물.
  30. Y가(여기서, R은 저급 알킬이다)인 일반식(I)의 화합물 및 약제학적으로 허용되는 담체를 포함하는 약제학적 조성물
  31. 소염제, 알레르기 치료제 또는 세포보호제로서 사용하기 위한 약제를 제조하기 위한, 제1항 또는 제3항에 따른 일반식(I)의 화합물 또는 약제학적으로 허용되는 이의 염의 용도.
  32. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019930700676A 1990-09-06 1991-09-05 소염제/알레르기 치료제로서의 나프탈렌프로피온산 유도체 KR930702306A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/578,367 1990-09-06
US07/578,367 US5084575A (en) 1987-07-31 1990-09-06 Quinoline substituted naphthalenepropionic acid derivatives as anti-inflammatory/antiallergic agents
PCT/US1991/006379 WO1992004325A1 (en) 1990-09-06 1991-09-05 Naphthalenepropionic acid derivatives as anti-inflammatory/antiallergic agents

Publications (1)

Publication Number Publication Date
KR930702306A true KR930702306A (ko) 1993-09-08

Family

ID=24312564

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930700676A KR930702306A (ko) 1990-09-06 1991-09-05 소염제/알레르기 치료제로서의 나프탈렌프로피온산 유도체

Country Status (9)

Country Link
US (1) US5084575A (ko)
EP (1) EP0547148A1 (ko)
JP (1) JPH06500997A (ko)
KR (1) KR930702306A (ko)
AU (1) AU654292B2 (ko)
CA (1) CA2089262A1 (ko)
IE (1) IE913128A1 (ko)
PT (1) PT98880A (ko)
WO (1) WO1992004325A1 (ko)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208344A (en) * 1987-07-31 1993-05-04 American Home Products Corporation Naphthalenepropionic acid derivatives as anti-inflammatory/antiallergic agents
US5250693A (en) * 1987-07-31 1993-10-05 American Home Products Corporation Quinolinylmethoxy naphthalenepropionic acid derivatives as anti-inflammatory/antiallergic agents
US5218124A (en) * 1989-10-27 1993-06-08 American Home Products Corporation Substituted benzoylbenzene-, biphenyl- and 2-oxazole-alkanoic acid derivatives as inhibitors of pla2 and lipoxygenase
DE4123341A1 (de) * 1991-07-15 1993-01-21 Thomae Gmbh Dr K Phenylalkylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US5260316A (en) * 1991-07-30 1993-11-09 Ciba-Geigy Corporation Isoquinolyl substituted hydroxylamine derivatives
US5334600A (en) * 1991-07-30 1994-08-02 Ciba-Geigy Corporation Isoquinolyl substituted hydroxylamine derivatives
US5350761A (en) * 1991-07-30 1994-09-27 Ciba-Geigy Corporation Indolyl substituted hydroxylamine derivatives
ES2103181B1 (es) * 1994-08-01 1998-04-01 Menarini Lab Amidas naftalenicas con accion antagonista de los leucotrienos.
SE9400809D0 (sv) * 1994-03-10 1994-03-10 Pharmacia Ab New use of quinoline-3-carboxamide compounds
US5811453A (en) 1994-12-23 1998-09-22 Alcon Laboratories, Inc. Viscoelastic compositions and methods of use
US5607966A (en) * 1994-12-23 1997-03-04 Alcon Laboratories, Inc. Esters and amides of non-steroidal anti-inflammatory carboxylic acids which may be used as anti-oxidants, 5-lipoxygenase inhibitors and non-steroidal anti-inflammatory prodrugs
US5643943A (en) * 1994-12-23 1997-07-01 Alcon Laboratories, Inc. Systemic administration of esters and amides of antioxidants which may be used as antioxidant prodrug therapy for oxidative and inflammatory pathogenesis
US5750564A (en) * 1995-09-12 1998-05-12 Hellberg; Mark Anti-oxidant esters of non-steroidal anti-inflammatory agents
ES2117551B1 (es) * 1995-12-29 1999-04-01 Menarini Lab Quinolinas naftalenicas con accion antagonista de los leucotrienos, procedimiento para su preparacion y utilizacion de las mismas.
US6630496B1 (en) 1996-08-26 2003-10-07 Genetics Institute Llc Inhibitors of phospholipase enzymes
US6828344B1 (en) 1998-02-25 2004-12-07 Genetics Institute, Llc Inhibitors of phospholipase enzymes
US6916841B2 (en) * 1998-02-25 2005-07-12 Genetics Institute, Llc Inhibitors of phospholipase enzymes
US6500853B1 (en) 1998-02-28 2002-12-31 Genetics Institute, Llc Inhibitors of phospholipase enzymes
GB2405146A (en) * 2002-06-07 2005-02-23 Cortical Pty Ltd Napthalene derivatives which inhibit the cytokine or biological activity of macrophage migration inhibitory factor (MIF)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3904682A (en) * 1967-01-13 1975-09-09 Syntex Corp 2-(6{40 -Methoxy-2{40 -naphthyl)acetic acid
US4097674A (en) * 1975-03-17 1978-06-27 Syntex Corporation 2-Naphthylacetic acid derivatives
DE3048610A1 (de) * 1980-12-23 1982-07-29 Hoechst Ag, 6000 Frankfurt "disazoverbindungen, verfahren zu ihrer herstellung und ihre verwendung"
US4794188A (en) * 1982-12-01 1988-12-27 Usv Pharmaceutical Corporation Certain unsymmetrical quinolinyl ethers having anti-inflammatory and anti-allergic activity
US4661596A (en) * 1985-02-21 1987-04-28 American Home Products Corporation Quinolinyl (or pyridinyl) methoxy substituted naphthalene compounds as antiallergic agents
US4631287A (en) * 1985-04-16 1986-12-23 Usv Pharmaceutical Corp. Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments
US4754043A (en) * 1985-10-03 1988-06-28 American Home Products Corporation Oxazole and thiazole naphthalenes as antiallergic agents
US4772703A (en) * 1986-01-27 1988-09-20 American Home Products Corporation 2-(phenoxymethyl)-quinazolines as antiallergic and antiinflammatory agents
DE3888574T2 (de) * 1987-04-24 1994-06-30 Abbott Lab Harnstoff-Derivate mit lipoxygenasehemmender Wirkung.
US4960892A (en) * 1988-06-10 1990-10-02 American Home Products Corporation Naphthalenepropionic acid derivatives as anti-inflammatory/anti-allergic agents
AU611699B2 (en) * 1987-07-31 1991-06-20 American Home Products Corporation Naphthalene propionic acid derivatives
US4937373A (en) * 1988-12-08 1990-06-26 Hoffmann-La Roche Inc. Substituted naphthalene carboxylic acids
WO1990012008A1 (en) * 1989-03-30 1990-10-18 Abbott Laboratories Urea based lipoxygenase inhibiting compounds
IL133435A0 (en) * 1997-06-12 2001-04-30 Northrop Grumman Corp Heat resistant composite structure

Also Published As

Publication number Publication date
WO1992004325A1 (en) 1992-03-19
PT98880A (pt) 1992-07-31
JPH06500997A (ja) 1994-01-27
AU8617191A (en) 1992-03-30
AU654292B2 (en) 1994-11-03
CA2089262A1 (en) 1992-03-07
EP0547148A1 (en) 1993-06-23
IE913128A1 (en) 1992-03-11
US5084575A (en) 1992-01-28

Similar Documents

Publication Publication Date Title
KR930702306A (ko) 소염제/알레르기 치료제로서의 나프탈렌프로피온산 유도체
EP0132366B1 (en) Leukotriene antagonists
EP1036058B1 (en) Adamantane derivatives
US4386080A (en) Anti-androgenic amide derivative
EP0291916B1 (en) Dithioacetal compounds, processes for preparation thereof and pharmaceutical composition comprising the same
EP0002309B1 (en) Acylanilides, process for their manufacture and pharmaceutical and veterinary compositions containing them
EP0025692B1 (en) Quinone derivatives, their production and use
FI77847B (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara alkensyraderivat.
EP0108592A1 (en) Leukotriene antagonists
NO164974B (no) Analogifremgangsmaate for fremstilling av et acylanilid med farmakologisk effekt.
WO1996030329A1 (en) Substituted benzene derivatives useful as neuraminidase inhibitors
JPS58103356A (ja) １３，１４−ジデヒドロプロスタグランジンのエステルおよびアミド誘導体
EP0465802A1 (en) Oxidant sensitive and insensitive aromatic esters as inhibitors of human neutrophil elastase
DE3342624A1 (de) Benzaronderivate, verfahren zu ihrer herstellung und diese derivate enthaltende arzneimittel
GB1561731A (en) Process for the preparation of benzopyrane derivatives
EP0059108B1 (en) Derivatives of dihydroxybenzoic acid
US3951954A (en) Novel oxofuryl ester derivatives of penicillin and cephalosporin
DE69812079T2 (de) Verfahren zur herstellung eines buthylthuio-isochinolinderivates und zwischenprodukte dafür
US4775662A (en) Leukotriene antagonists
EP0481891B1 (en) Phenoxyacetic acid compounds, method for production thereof, and pharmaceutical preparations containing same
JPS61268651A (ja) フエニル酢酸誘導体およびその製造法
GB1600127A (en) Piperazine-dione derivatives
KR0156537B1 (ko) N-하이드록시-디벤즈(b,e)옥세핀-알킬아민과-알카노산 아미드 및 이들의 헤테로사이클릭 동족체, 이들의 제조방법 및 이들을 함유하는 약제학적 조성물
US3948955A (en) 4'-Carboxy-flavone
CA1283250C (en) Cyclohexanealkanoic acids

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid